Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Verzenios ® ▼ (abemaciclib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Should Verzenios® (abemaciclib) be paused before and held after surgery?
In the Monarch studies, abemaciclib was held at least 7 days before surgery and continued no earlier than 14 days after completion of surgery ± radiotherapy. In monarchE, abemaciclib was resumed after surgery as clinically indicated.
Use of Abemaciclib During Invasive Procedures
Information on holding abemaciclib treatment for surgery is available in several clinical study protocols and is provided in this response. No additional information is available on the use of abemaciclib during invasive procedures or on the outcomes in patients who underwent surgery while on study.
Patients Undergoing Surgery in MONARCH 2 and MONARCH 3
Such a patient should not receive study treatment for the period beginning at least 7 days prior to surgery and continuing until at least 14 days after completion of surgery ± radiotherapy to allow for tissue healing and recovery.1,2